Published Date:2023-06-09 Original Link:https://www.onenessbio.com/en/news_detail226_3.htm No 1 Date of announcement 2023/06/09 Time of announcement 17:31:30 Subject Oneness submitted an IND to TFDA for a phase II clinical trial on the broad-spectrum anti-SARS-CoV-2 siRNA (SNS812) co-developed with Microbio (Shanghai) To which item it meets paragraph 10 Date of events 2023/06/09 Statement Product:SNS812, a broad-spectrum siRNA against SARS-CoV-2...Read More